Patient P-02057

Synthetic patientMETA-24 · Day 179 · 55–64 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

77%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 24 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 79 GI-04 recommended — GI Support Protocol GI-04
Day 80 Patient accepted — Started GI-04 in the companion
Day 88 GI symptom burden −30% vs expected — GI Support Protocol GI-04
Day 94 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 24.

Primary contributors, last 14 days

GI instability-11
Nutritional resilience+8
Inflammatory activity-4
Toxicity-4
Treatment adherence+3

What helped?

GI Support Protocol GI-04Day 79
Result: symptom burden −30%

LIFE OS recommendation

Monitoring Escalation ME-01

88%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

40 min

worsening · -1.6 vs previous 14 d

Sleep duration

Wearable

5.7 h

stable · +0.1 vs previous 14 d

Energy level

Daily log

2.3/10

worsening · -0.2 vs previous 14 d

Steps

Wearable

3,387

stable · -66 vs previous 14 d

GI burden

Companion

67.5/100

improving · -3.9 vs previous 14 d

Adherence

Companion

45.2 %

worsening · -2.7 vs previous 14 d

Sleep quality

Wearable

11/100

improving · +1.8 vs previous 14 d

Glucose, CGM daily mean

CGM

160 mg/dL

stable · +1.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 23 from the failing basin, 72 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 76%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 76%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 76%
More protein
GI -7.6 next day on high-intake days · n 23

Would not help

Keep fat low
GI +7.2 next day on high-intake days · n 21
Keep alcohol low
GI +6.9 next day on high-intake days · n 22
Keep fibre low
GI +6.7 next day on high-intake days · n 15

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-7.6supporter · 95%
Dietary fat load
+7.2detractor · 95%
Alcohol
+6.9detractor · 95%
Insoluble fibre
+6.7detractor · 95%
Ultra-processed food
+6.7detractor · 95%
Histamine load
+6.5detractor · 95%
Caffeine
+2no signal · 29%
Simple carbohydrates
+0.8no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 68 and rising
- WearableSleep 5.7 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 64
- WearableHRV 16 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 85 bpm
- Wearable3,387 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 49

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 39/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 5.7 h
Steps: 2,828
Resting HR: 85 bpm

Daily log: GI score 68, nutritional resilience 37, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02505	62%	S14	NP-02	improved	45
P-02542	56%	S14	NP-02	improved	44
P-02094	52%	S14	NP-02	improved	53
P-02582	52%	S14	ME-01	improved	45
P-02014	51%	S14	GI-04	improved	48
P-02574	51%	S14	ME-01	improved	45
P-02348	50%	S14	GI-04	improved	49
P-02628	50%	S14	SC-12	improved	47
P-02648	48%	S14	SC-12	improved	47
P-02297	47%	S02	NP-02	improved	49
P-02643	47%	S14	SC-12	improved	46
P-02118	46%	S14	GI-04	improved	47